Prot# D5170C00002: A Phase 2b Double-blind, Multi-dose, Placebo-controlled Study to Evaluate the Efficacy and Safety of MEDI2070 in Subjects with Moderate to Severe Crohn’s Disease Who Have Failed or Are Intolerant to Anti-tumor Necrosis Factor-alpha Ther

Project: Research project

Project Details

Effective start/end date11/7/1611/7/19


  • Quintiles, Inc. (Prot# D5170C00002 // Prot# D5170C00002)
  • MedImmune, LLC (Prot# D5170C00002 // Prot# D5170C00002)